Respiratory Mechanics Effects of Flutter Valve in Bronchiectasis Patients
|ClinicalTrials.gov Identifier: NCT00656721|
Recruitment Status : Completed
First Posted : April 11, 2008
Last Update Posted : June 22, 2015
|Condition or disease||Intervention/treatment|
|Bronchiectasis||Device: Flutter Valve|
The application of airway clearance techniques is considered an important component in the treatment of bronchiectasis patients (Van der Shans, 1997). For this purpose, a number of techniques has been introduced in the last decades. The Flutter Valve was initially proposed for the treatment of children with cystic fibrosis (CF) (Lindemann, 1992), but there is not enough evidence about its utilization in patients with bronchiectasis (Van der Shans & cols, 1999).
The effects of the Flutter Valve on respiratory mechanics of patients with bronchiectasis have been evaluated by forced spirometry (Pryor e cols, 1994; Gondor e cols, 1999; Thompson e cols, 2002). This approach however, does not allow the characterization of mucus transportation along the airways (Williams, 1994). The forced oscillation technique (FOT), a non-invasive alternative to characterize respiratory mechanics, allows the evaluation of respiratory mechanics at different frequencies without special maneuvers (Dubois e cols., 1956). According to eligibility criteria and in a randomized order, the patients were submitted to two protocols (control and Flutter Valve intervention), with one-week interval between them (washout). Respiratory mechanics and expectorated sputum volume were assessed before and after each intervention, in order to assess the Flutter Valve effect on tracheobronchial sputum removal.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||8 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Flutter Valve Improves Respiratory Mechanics and Sputum Production in Bronchiectasis Patients|
|Study Start Date :||September 2004|
|Primary Completion Date :||November 2005|
|Study Completion Date :||June 2006|
Experimental: Flutter Valve
This a crossover study, so all subjects performed both, control and experimental interventions. In Flutter Valve intervention the subjects remained comfortably seated, breathing through the device for 15 minutes, starting off from the total pulmonary capacity, and being free to cough. Thereafter, a 5-min session of cough ensued. In the control intervention the subjects followed the same sequence of the Flutter Valve intervention, but the metallic sphere and the cover of the device were removed. Since the patients were not acquainted with the valve, they did not know its proper assembly. As in the Flutter Valve intervention, during 15 minutes the patients could expectorate spontaneously and return to the device. A 5-min coughing session took place.
Device: Flutter Valve
Flutter Valve (Scandipharm, Birmingham, AL) is shaped like a pipe with a hardened plastic mouthpiece at one end, a plastic protective, perforated cover at the other end, and a high-density stainless steel ball resting in a plastic circular cone on the inside. When the patient expires, a vibratory effect is transmitted to airways by the steel ball oscillation in order to facilitate mucociliary clearance.
In our study, the use of the equipment was guided by a registered physical therapist, but the position (angle) was determined by the patient, according to his/her adaptation and perception of effectiveness of sputum clearance. The patients remained comfortably seated, breathing through the device for 15 minutes, starting from the total pulmonary capacity, and being free to cough. Thereafter, a 5-minute session of cough was done.
Other Name: FLUTTER® Mucus Clearance Device
- Expectorated sputum volume. [ Time Frame: After each evaluated procedure (control and Flutter Valve intervention) ]
- Respiratory mechanics (spectral data recorded by impulse oscillation technique). [ Time Frame: Before and after each applied procedure (control and Flutter Valve intervention) ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00656721
|Universidade Federal do Rio de Janeiro|
|Rio de Janeiro, Brazil, 21941-902|
|Hospital Universitário Clementino Fraga Filho|
|Rio de Janeiro, Brazil, 21949-900|
|Study Chair:||Fernando S Guimarães, PhD||Universidade Federal do Rio de Janeiro|